[HTML][HTML] Therapeutic targeting of the Ang2/tie pathway in endothelial cells as a potential treatment of hereditary hemorrhagic telangiectasia
C Bernabeu - Arteriosclerosis, Thrombosis, and Vascular Biology, 2023 - Am Heart Assoc
Arteriosclerosis, Thrombosis, and Vascular Biology, 2023•Am Heart Assoc
Thrombosis, and Vascular Biology, Zhou et al1 present experimental evidences that
pharmacological blockade of Ang2 (angiopoietin-2)—a key regulator of angiogenesis—
prevents and improves the vascular lesions in the brain of 3 different genetic mouse models
of HHT, suggesting that Ang2-targeted therapies could be used in patients with HHT. This
exciting discovery opens up a new research avenue for therapeutic prevention and
treatment of vascular malformations in HHT.
pharmacological blockade of Ang2 (angiopoietin-2)—a key regulator of angiogenesis—
prevents and improves the vascular lesions in the brain of 3 different genetic mouse models
of HHT, suggesting that Ang2-targeted therapies could be used in patients with HHT. This
exciting discovery opens up a new research avenue for therapeutic prevention and
treatment of vascular malformations in HHT.
Thrombosis, and Vascular Biology, Zhou et al1 present experimental evidences that pharmacological blockade of Ang2 (angiopoietin-2)—a key regulator of angiogenesis—prevents and improves the vascular lesions in the brain of 3 different genetic mouse models of HHT, suggesting that Ang2-targeted therapies could be used in patients with HHT. This exciting discovery opens up a new research avenue for therapeutic prevention and treatment of vascular malformations in HHT.
Am Heart Assoc